Drug Target Review Screening ebook 2021

Posted: 18 June 2021 | | No comments yet

This ebook has articles on the use of screening to identify COVID-19 drugs and how assessing compound activity could accelerate drug discovery.

Screening is a vital tool in a researcher’s kit to identify new, or repurpose existing, drugs. In this ebook, learn about how screening can be applied and how challenges relating to the method can be overcome. 

In this collection of articles, Dr Matthew Lloyd explains why false positive hits can arise during drug discovery and Professor Arvind Patel describes a new project at the University of Glasgow to screen for COVID-19 therapeutics. Elsewhere, discover how drugs targeting phosphodiesterase 3A to treat sarcoma were identified and why a collaboration between the Francis Crick Institute and GlaxoSmithKline for covalent fragment screening has been formed.

Included in this ebook: 

  • Why some screening hits are a PAIN
    Dr Matthew Lloyd, University of Bath
  • Assessing compound activity to accelerate drug discovery
    Victoria Rees, Drug Target Review
  • Screening for COVID-19 drugs
    Professor Arvind Patel, University of Glasgow
  • Targeting phosphodiesterase 3A: discovery of a promising cancer therapy
    Dr Harri Sihto, University of Helsinki
    Dr Katja Ivanitskiy and Professor Olli Kallioniemi, Sartar Therapeutics
  • Covalent fragment screening in cell‑based phenotypic models of disease: a collaborative approach
    Dr Andrew Powell, Dr Jacob Bush and Dr David House, GlaxoSmithKline (GSK)
    Dr Katrin Rittinger and Dr Simon Boulton, The Francis Crick Institute

    To read this ebook in full, please complete the form below:


    This specialist content is provided to you free-of-charge thanks to the kind support of Beckman Coulter, Horizon Discovery, Merck and X-Chem

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.